PMC3465891_01
Dorsal view of the necrotic ulcer on the glans penis.
CRIM.PATHOLOGY2012-948352.001.jpg
PMC3465891_01_CRIM.PATHOLOGY2012-948352.001.jpg
fig1
His physical examination revealed a large well-demarcated penile ulcer with a necrotic base (Figure 1).
Sonographic imaging of the case. (a) Transabdominal US of the pelvis (sagittal section) shows an enlarged and markedly hypoechoic prostate (asterisk), with indistinct borders. Irregular thickening of the bladder wall is also noted (arrow). (b) Transrectal US confirms infiltration of the prostate by a bulky, lobulated, hypoechoic mass (arrows) which also involves the base of the penis. (c) Transabdominal US (comparable section with (a)) shows resolution of the infiltrative process.
CRIM.PATHOLOGY2012-948352.002.jpg
PMC3465891_01_CRIM.PATHOLOGY2012-948352.002.jpg
fig2
The prostate was enlarged (volume: 80 mL), hypoechoic and with indistinct borders (Figure 2(a)). Transrectal US examination showed that the shaft of the penis and the right prostate lobe were infiltrated by a solid, ill-defined, hypoechoic mass (Figure 2(b)). In the posttreatment transabdominal US the bladder and prostate lesions also had completely resolved (Figure 2(c)).
Pathology image.
CRIM.PATHOLOGY2012-948352.003.jpg
PMC3465891_01_CRIM.PATHOLOGY2012-948352.003.jpg
fig3
The immunophenotyping showed positive staining, diffusely for LCA, CD19, CD20, CD79 and focally for CD3, CD5, CD68, and no staining for epithelial and neuroendocrine markers or melanoma-specific markers (Figures 3, 4, and 5).
Pathology image (CD19 immunostain).
CRIM.PATHOLOGY2012-948352.004.jpg
PMC3465891_01_CRIM.PATHOLOGY2012-948352.004.jpg
fig4
The immunophenotyping showed positive staining, diffusely for LCA, CD19, CD20, CD79 and focally for CD3, CD5, CD68, and no staining for epithelial and neuroendocrine markers or melanoma-specific markers (Figures 3, 4, and 5).
Pathology image (CD30 immunostain).
CRIM.PATHOLOGY2012-948352.005.jpg
PMC3465891_01_CRIM.PATHOLOGY2012-948352.005.jpg
fig5
The immunophenotyping showed positive staining, diffusely for LCA, CD19, CD20, CD79 and focally for CD3, CD5, CD68, and no staining for epithelial and neuroendocrine markers or melanoma-specific markers (Figures 3, 4, and 5).